Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Dan Hung Barouch, M.D.

TitleProfessor of Medicine
InstitutionBeth Israel Deaconess Medical Center
DepartmentMedicine
AddressBeth Israel Deaconess Med Ctr
735-4566e/cls-1047
330 Brookline Ave
Boston MA 02215
Phone617/735-4485
Fax617/735-4566

 Mentoring 
 current student opportunities
Available: 09/01/11, Expires: 08/31/15

The development of a safe and effective vaccine is critical for ending the HIV/AIDS pandemic. Novel vector-based and protein-based vaccine candidates will be required. The student will work to develop and to assess novel vaccine technologies as potential HIV/AIDS vaccine candidates in preclinical studies.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Del Prete GQ, Scarlotta M, Newman L, Reid C, Parodi LM, Roser JD, Oswald K, Marx PA, Miller CJ, Desrosiers RC, Barouch DH, Pal R, Piatak M, Chertova E, Giavedoni LD, O'Connor DH, Lifson JD, Keele BF. Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol. 2013 Apr; 87(8):4584-95.
    View in: PubMed
  2. Im EJ, Borducchi EN, Provine NM, McNally AG, Li S, Frankel FR, Barouch DH. An Attenuated Listeria monocytogenes Vector Primes More Potent Simian Immunodeficiency Virus-Specific Mucosal Immunity than DNA Vaccines in Mice. J Virol. 2013 Apr; 87(8):4751-5.
    View in: PubMed
  3. Demuth PC, Min Y, Huang B, Kramer JA, Miller AD, Barouch DH, Hammond PT, Irvine DJ. Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater. 2013 Apr; 12(4):367-76.
    View in: PubMed
  4. Yusim K, Dilan R, Borducchi E, Stanley K, Giorgi E, Fischer W, Theiler J, Marcotrigiano J, Korber B, Barouch DH. Hepatitis C genotype 1 mosaic vaccines are immunogenic in mice and induce stronger T-cell responses than natural strains. Clin Vaccine Immunol. 2013 Feb; 20(2):302-5.
    View in: PubMed
  5. Tan WG, Jin HT, West EE, Penaloza-Macmaster P, Wieland A, Zilliox MJ, McElrath MJ, Barouch DH, Ahmed R. Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8+ T Cells Induced by Different Adenovirus Vectors. J Virol. 2013 Feb; 87(3):1359-72.
    View in: PubMed
  6. Penaloza-Macmaster P, Provine NM, Ra J, Borducchi EN, McNally A, Simmons NL, Iampietro MJ, Barouch DH. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to ad5 vectors. J Virol. 2013 Feb; 87(3):1373-84.
    View in: PubMed
  7. Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, McElrath MJ, Wenschuh H, Reimer U, Seaman MS, Pau MG, Weijtens M, Goudsmit J, Walsh SR, Dolin R, Baden LR. Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). J Infect Dis. 2013 Jan; 207(2):248-56.
    View in: PubMed
  8. Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, Zablowsky E, Abbink P, Peter L, Iampietro MJ, Cheung A, Pau MG, Weijtens M, Goudsmit J, Swann E, Wolff M, Loblein H, Dolin R, Barouch DH. First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001). J Infect Dis. 2013 Jan; 207(2):240-7.
    View in: PubMed
  9. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, Kaufmann DE, McElrath MJ, Nussenzweig MC, Pulendran B, Scanlan CN, Schief WR, Silvestri G, Streeck H, Walker BD, Walker LM, Ward AB, Wilson IA, Wyatt R. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 2012 Oct 18; 12(4):396-407.
    View in: PubMed
  10. Handley SA, Thackray LB, Zhao G, Presti R, Miller AD, Droit L, Abbink P, Maxfield LF, Kambal A, Duan E, Stanley K, Kramer J, Macri SC, Permar SR, Schmitz JE, Mansfield K, Brenchley JM, Veazey RS, Stappenbeck TS, Wang D, Barouch DH, Virgin HW. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell. 2012 Oct 12; 151(2):253-66.
    View in: PubMed
  11. Coughlan L, Bradshaw AC, Parker AL, Robinson H, White K, Custers J, Goudsmit J, Van Roijen N, Barouch DH, Nicklin SA, Baker AH. Ad5:ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther. 2012 Dec; 20(12):2268-81.
    View in: PubMed
  12. Stephenson KE, SanMiguel A, Simmons NL, Smith K, Lewis MG, Szinger JJ, Korber B, Barouch DH. Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys. J Virol. 2012 Nov; 86(21):11434-40.
    View in: PubMed
  13. Li H, Rhee EG, Masek-Hammerman K, Teigler JE, Abbink P, Barouch DH. Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J Virol. 2012 Oct; 86(19):10862-5.
    View in: PubMed
  14. Teigler JE, Iampietro MJ, Barouch DH. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J Virol. 2012 Sep; 86(18):9590-8.
    View in: PubMed
  15. Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, Seaman MS, Barouch DH, Chen B. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A. 2012 Jul 24; 109(30):12111-6.
    View in: PubMed
  16. Stephenson KE, Li H, Walker BD, Michael NL, Barouch DH. Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. J Virol. 2012 Sep; 86(18):9583-9.
    View in: PubMed
  17. Liu J, Li H, Iampietro MJ, Barouch DH. Accelerated heterologous adenovirus prime-boost SIV vaccine in neonatal rhesus monkeys. J Virol. 2012 Aug; 86(15):7829-35.
    View in: PubMed
  18. Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proc Natl Acad Sci U S A. 2012 May 29; 109(22):8694-8.
    View in: PubMed
  19. Stephenson KE, Hural J, Buchbinder SP, Sinangil F, Barouch DH. Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. J Infect Dis. 2012 Jun 15; 205(12):1806-10.
    View in: PubMed
  20. Perreau M, Welles HC, Pellaton C, Gjoksi B, Potin L, Martin R, Harari A, Bett A, Casimiro D, Gall J, Barouch DH, Kremer EJ, Pantaleo G. The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes. J Virol. 2012 Jun; 86(11):6279-85.
    View in: PubMed
  21. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal DN, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, Michael NL. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012 Feb 2; 482(7383):89-93.
    View in: PubMed
  22. Kaufman DR, Li F, Cruz AN, Self SG, Barouch DH. Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. Vaccine. 2012 Jan 11; 30(3):506-9.
    View in: PubMed
  23. Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol. 2012 Jan; 86(2):1267-72.
    View in: PubMed
  24. Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol. 2012 Jan; 86(1):625-9.
    View in: PubMed
  25. Baden LR, Blattner WA, Morgan C, Huang Y, Defawe OD, Sobieszczyk ME, Kochar N, Tomaras GD, McElrath MJ, Russell N, Brandariz K, Cardinali M, Graham BS, Barouch DH, Dolin R. Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. J Infect Dis. 2011 Nov 15; 204(10):1541-9.
    View in: PubMed
  26. Li H, Liu J, Carville A, Mansfield KG, Lynch D, Barouch DH. Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys. J Virol. 2011 Nov; 85(21):11007-15.
    View in: PubMed
  27. Kaufman DR, De Calisto J, Simmons NL, Cruz AN, Villablanca EJ, Mora JR, Barouch DH. Vitamin A deficiency impairs vaccine-elicited gastrointestinal immunity. J Immunol. 2011 Aug 15; 187(4):1877-83.
    View in: PubMed
  28. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96. J Immunol. 2011 Jul 1; 187(1):7-9.
    View in: PubMed
  29. Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P, Sinangil F, de Bruyn G, Gray GE, Roux S, Bekker LG, Dilraj A, Kibuuka H, Robb ML, Michael NL, Anzala O, Amornkul PN, Gilmour J, Hural J, Buchbinder SP, Seaman MS, Dolin R, Baden LR, Carville A, Mansfield KG, Pau MG, Goudsmit J. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011 Jul 18; 29(32):5203-9.
    View in: PubMed
  30. Ndhlovu ZM, Piechocka-Trocha A, Vine S, McMullen A, Koofhethile KC, Goulder PJ, Ndung'u T, Barouch DH, Walker BD. Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells. J Immunol. 2011 Jun 15; 186(12):6914-24.
    View in: PubMed
  31. Wilks AB, Christian EC, Seaman MS, Sircar P, Carville A, Gomez CE, Esteban M, Pantaleo G, Barouch DH, Letvin NL, Permar SR. Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J Immunol. 2010 Dec 1; 185(11):7097-106.
    View in: PubMed
  32. Rhee EG, Blattman JN, Kasturi SP, Kelley RP, Kaufman DR, Lynch DM, La Porte A, Simmons NL, Clark SL, Pulendran B, Greenberg PD, Barouch DH. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol. 2011 Jan; 85(1):315-23.
    View in: PubMed
  33. Barouch DH. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS. 2010 Sep; 5(5):386-90.
    View in: PubMed
  34. Masek-Hammerman K, Li H, Liu J, Abbink P, La Porte A, O'Brien KL, Whitney JB, Carville A, Mansfield KG, Barouch DH. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5. J Virol. 2010 Oct; 84(19):9810-6.
    View in: PubMed
  35. Liu J, Keele BF, Li H, Keating S, Norris PJ, Carville A, Mansfield KG, Tomaras GD, Haynes BF, Kolodkin-Gal D, Letvin NL, Hahn BH, Shaw GM, Barouch DH. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol. 2010 Oct; 84(19):10406-12.
    View in: PubMed
  36. Rhee EG, Kelley RP, Agarwal I, Lynch DM, La Porte A, Simmons NL, Clark SL, Barouch DH. TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector. J Virol. 2010 Oct; 84(19):10413-9.
    View in: PubMed
  37. Lim SY, Chan T, Gelman RS, Whitney JB, O'Brien KL, Barouch DH, Goldstein DB, Haynes BF, Letvin NL. Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys. PLoS Genet. 2010 Jun; 6(6):e1000997.
    View in: PubMed
  38. Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, Markowitz M, Little S, Sax PE, Collier AC, Nabel G, Saindon S, Flynn T, Kuritzkes D, Barouch DH. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One. 2010; 5(5):e10555.
    View in: PubMed
  39. Kaufman DR, Bivas-Benita M, Simmons NL, Miller D, Barouch DH. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol. 2010 Jun; 84(12):5986-96.
    View in: PubMed
  40. Barouch DH, O'Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, Clark SL, Backus K, Perry JR, Seaman MS, Carville A, Mansfield KG, Szinger JJ, Fischer W, Muldoon M, Korber B. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med. 2010 Mar; 16(3):319-23.
    View in: PubMed
  41. Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE, Devoy C, Lynch DM, La Porte A, Simmons NL, Bradley R, Montefiori DC, Seaman MS, Chen B, Barouch DH. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J Virol. 2010 Apr; 84(7):3270-9.
    View in: PubMed
  42. Barouch DH, Korber B. HIV-1 vaccine development after STEP. Annu Rev Med. 2010; 61:153-67.
    View in: PubMed
  43. Hudgens MG, Gilbert PB, Mascola JR, Wu CD, Barouch DH, Self SG. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J Infect Dis. 2009 Aug 15; 200(4):609-13.
    View in: PubMed
  44. Kaufman DR, Barouch DH. Translational Mini-Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine-elicited mucosal immunity. Clin Exp Immunol. 2009 Aug; 157(2):165-73.
    View in: PubMed
  45. Rhee EG, Barouch DH. Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development. Clin Exp Immunol. 2009 Aug; 157(2):174-80.
    View in: PubMed
  46. O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW, Robertson MN, Casimiro DR, Barouch DH. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med. 2009 Aug; 15(8):873-5.
    View in: PubMed
  47. Barouch DH, Liu J, Lynch DM, O'Brien KL, La Porte A, Simmons NL, Riggs AM, Clark S, Abbink P, Montefiori DC, Landucci G, Forthal DN, Self SG, Carville A, Mansfield K, Goudsmit J. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol. 2009 Sep; 83(18):9584-90.
    View in: PubMed
  48. Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, Nicklin SA, van Rooijen N, Custers J, Goudsmit J, Barouch DH, McVey JH, Baker AH. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood. 2009 Jul 30; 114(5):965-71.
    View in: PubMed
  49. Grandpre LE, Duke-Cohan JS, Ewald BA, Devoy C, Barouch DH, Letvin NL, Reinherz EL, Baden LR, Dolin R, Seaman MS. Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. Vaccine. 2009 Mar 4; 27(10):1549-56.
    View in: PubMed
  50. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2009 Jan 1; 457(7225):87-91.
    View in: PubMed
  51. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008 Oct 2; 455(7213):613-9.
    View in: PubMed
  52. Barefoot B, Thornburg NJ, Barouch DH, Yu JS, Sample C, Johnston RE, Liao HX, Kepler TB, Haynes BF, Ramsburg E. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine. 2008 Nov 11; 26(48):6108-18.
    View in: PubMed
  53. Kaufman DR, Liu J, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH. Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination. J Immunol. 2008 Sep 15; 181(6):4188-98.
    View in: PubMed
  54. Barouch DH. HIV vaccine trial canceled. AIDS Clin Care. 2008 Sep; 20(9):69.
    View in: PubMed
  55. Santra S, Korber BT, Muldoon M, Barouch DH, Nabel GJ, Gao F, Hahn BH, Haynes BF, Letvin NL. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A. 2008 Jul 29; 105(30):10489-94.
    View in: PubMed
  56. Barouch DH. Bovine adenovirus vectored vaccine for avian influenza. Mol Ther. 2008 May; 16(5):807-8.
    View in: PubMed
  57. Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice. J Virol. 2008 Jul; 82(14):6829-37.
    View in: PubMed
  58. Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol. 2008 Jun; 82(11):5643-9.
    View in: PubMed
  59. Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AA, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol. 2008 May; 82(10):4844-52.
    View in: PubMed
  60. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J, Morita T, Francischetti IM, Monteiro RQ, Barouch DH, van Rooijen N, Napoli C, Havenga MJ, Nicklin SA, Baker AH. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008 Feb 8; 132(3):397-409.
    View in: PubMed
  61. Barouch DH. HIV-1 vaccine candidate ineffective. AIDS Clin Care. 2007 Nov; 19(11):93.
    View in: PubMed
  62. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007 May; 81(9):4654-63.
    View in: PubMed
  63. Thorner AR, Barouch DH. HIV-1 vaccine development: progress and prospects. Curr Infect Dis Rep. 2007 Jan; 9(1):71-5.
    View in: PubMed
  64. Thorner AR, Lemckert AA, Goudsmit J, Lynch DM, Ewald BA, Denholtz M, Havenga MJ, Barouch DH. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol. 2006 Dec; 80(24):12009-16.
    View in: PubMed
  65. Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, Dilraj A, McNally LM, Jeena PM, Jepsen S, Abbink P, Nanda A, Swanson PE, Bates AT, O'Brien KL, Havenga MJ, Goudsmit J, Barouch DH. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol. 2006 Oct; 44(10):3781-3.
    View in: PubMed
  66. Lemckert AA, Grimbergen J, Smits S, Hartkoorn E, Holterman L, Berkhout B, Barouch DH, Vogels R, Quax P, Goudsmit J, Havenga MJ. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol. 2006 Oct; 87(Pt 10):2891-9.
    View in: PubMed
  67. Liu J, Ewald BA, Lynch DM, Nanda A, Sumida SM, Barouch DH. Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J Virol. 2006 Dec; 80(24):11991-7.
    View in: PubMed
  68. Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol. 2006 Aug; 87(Pt 8):2135-43.
    View in: PubMed
  69. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006 May 11; 441(7090):239-43.
    View in: PubMed
  70. Barouch DH. Rational design of gene-based vaccines. J Pathol. 2006 Jan; 208(2):283-9.
    View in: PubMed
  71. Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol. 2005 Nov; 79(22):14161-8.
    View in: PubMed
  72. Peyerl FW, Barouch DH, Bazick HS, Manuel E, Letvin NL. Use of molecular beacons for rapid, real-time, quantitative monitoring of cytotoxic T-lymphocyte epitope mutations in simian immunodeficiency virus. J Clin Microbiol. 2005 Sep; 43(9):4773-9.
    View in: PubMed
  73. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol. 2005 Aug; 79(15):9694-701.
    View in: PubMed
  74. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, Kishko MG, Arthur JC, Miura A, Mascola JR, Letvin NL, Nabel GJ. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol. 2005 Jul; 79(14):8828-34.
    View in: PubMed
  75. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005 Jun 1; 174(11):7179-85.
    View in: PubMed
  76. Bielefeldt-Ohmann H, Barouch DH, Bakke AM, Bruce AG, Durning M, Grant R, Letvin NL, Ryan JT, Schmidt A, Thouless ME, Rose TM. Intestinal stromal tumors in a simian immunodeficiency virus-infected, simian retrovirus-2 negative rhesus macaque (Macaca mulatta). Vet Pathol. 2005 May; 42(3):391-6.
    View in: PubMed
  77. Santra S, Seaman MS, Xu L, Barouch DH, Lord CI, Lifton MA, Gorgone DA, Beaudry KR, Svehla K, Welcher B, Chakrabarti BK, Huang Y, Yang ZY, Mascola JR, Nabel GJ, Letvin NL. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol. 2005 May; 79(10):6516-22.
    View in: PubMed
  78. Sun Y, Schmitz JE, Acierno PM, Santra S, Subbramanian RA, Barouch DH, Gorgone DA, Lifton MA, Beaudry KR, Manson K, Philippon V, Xu L, Maecker HT, Mascola JR, Panicali D, Nabel GJ, Letvin NL. Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes. J Immunol. 2005 Apr 15; 174(8):4753-60.
    View in: PubMed
  79. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther. 2005 Feb; 16(2):149-56.
    View in: PubMed
  80. Barouch DH, Powers J, Truitt DM, Kishko MG, Arthur JC, Peyerl FW, Kuroda MJ, Gorgone DA, Lifton MA, Lord CI, Hirsch VM, Montefiori DC, Carville A, Mansfield KG, Kunstman KJ, Wolinsky SM, Letvin NL. Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants. Nat Immunol. 2005 Mar; 6(3):247-52.
    View in: PubMed
  81. Peyerl FW, Bazick HS, Newberg MH, Barouch DH, Sodroski J, Letvin NL. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol. 2004 Dec; 78(24):13901-10.
    View in: PubMed
  82. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev. 2004 Dec; 202:266-74.
    View in: PubMed
  83. Sumida SM, McKay PF, Truitt DM, Kishko MG, Arthur JC, Seaman MS, Jackson SS, Gorgone DA, Lifton MA, Letvin NL, Barouch DH. Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest. 2004 Nov; 114(9):1334-42.
    View in: PubMed
  84. Barouch DH, Truitt DM, Letvin NL. Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. Vaccine. 2004 Aug 13; 22(23-24):3092-7.
    View in: PubMed
  85. Santra S, Barouch DH, Korioth-Schmitz B, Lord CI, Krivulka GR, Yu F, Beddall MH, Gorgone DA, Lifton MA, Miura A, Philippon V, Manson K, Markham PD, Parrish J, Kuroda MJ, Schmitz JE, Gelman RS, Shiver JW, Montefiori DC, Panicali D, Letvin NL. Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci U S A. 2004 Jul 27; 101(30):11088-93.
    View in: PubMed
  86. Barouch DH, Letvin NL. HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines? Lancet. 2004 Jul 3-9; 364(9428):10-1.
    View in: PubMed
  87. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004 May 15; 172(10):6290-7.
    View in: PubMed
  88. McKay PF, Barouch DH, Santra S, Sumida SM, Jackson SS, Gorgone DA, Lifton MA, Letvin NL. Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol. 2004 Apr; 34(4):1011-20.
    View in: PubMed
  89. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA, Koudstaal W, Pau MG, Kostense S, Havenga MJ, Goudsmit J, Letvin NL, Barouch DH. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol. 2004 Mar; 78(6):2666-73.
    View in: PubMed
  90. Lemckert AA, Goudsmit J, Barouch DH. Challenges in the search for an HIV vaccine. Eur J Epidemiol. 2004; 19(6):513-6.
    View in: PubMed
  91. Peyerl FW, Barouch DH, Letvin NL. Structural constraints on viral escape from HIV- and SIV-specific cytotoxic T-lymphocytes. Viral Immunol. 2004; 17(2):144-51.
    View in: PubMed
  92. Peyerl FW, Barouch DH, Yeh WW, Bazick HS, Kunstman J, Kunstman KJ, Wolinsky SM, Letvin NL. Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J Virol. 2003 Dec; 77(23):12572-8.
    View in: PubMed
  93. Marty FM, Barouch DH, Coakley EP, Baden LR. Disseminated trichosporonosis caused by Trichosporon loubieri. J Clin Microbiol. 2003 Nov; 41(11):5317-20.
    View in: PubMed
  94. Mascola JR, Lewis MG, VanCott TC, Stiegler G, Katinger H, Seaman M, Beaudry K, Barouch DH, Korioth-Schmitz B, Krivulka G, Sambor A, Welcher B, Douek DC, Montefiori DC, Shiver JW, Poignard P, Burton DR, Letvin NL. Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J Virol. 2003 Oct; 77(19):10348-56.
    View in: PubMed
  95. Subbramanian RA, Kuroda MJ, Charini WA, Barouch DH, Costantino C, Santra S, Schmitz JE, Martin KL, Lifton MA, Gorgone DA, Shiver JW, Letvin NL. Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys. J Virol. 2003 Sep; 77(18):10113-8.
    View in: PubMed
  96. Barouch DH, McKay PF, Sumida SM, Santra S, Jackson SS, Gorgone DA, Lifton MA, Chakrabarti BK, Xu L, Nabel GJ, Letvin NL. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol. 2003 Aug; 77(16):8729-35.
    View in: PubMed
  97. Barouch DH, Kunstman J, Glowczwskie J, Kunstman KJ, Egan MA, Peyerl FW, Santra S, Kuroda MJ, Schmitz JE, Beaudry K, Krivulka GR, Lifton MA, Gorgone DA, Wolinsky SM, Letvin NL. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol. 2003 Jul; 77(13):7367-75.
    View in: PubMed
  98. McKay PF, Barouch DH, Schmitz JE, Veazey RS, Gorgone DA, Lifton MA, Williams KC, Letvin NL. Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination. J Virol. 2003 Apr; 77(8):4695-702.
    View in: PubMed
  99. Premenko-Lanier M, Rota PA, Rhodes G, Verhoeven D, Barouch DH, Lerche NW, Letvin NL, Bellini WJ, McChesney MB. DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. Virology. 2003 Mar 1; 307(1):67-75.
    View in: PubMed
  100. Barouch DH, Letvin NL. Viral evolution and challenges in the development of HIV vaccines. Vaccine. 2002 Dec 19; 20 Suppl 4:A66-8.
    View in: PubMed
  101. Barouch DH, Faquin WC, Chen Y, Koralnik IJ, Robbins GK, Davis BT. BK virus-associated hemorrhagic cystitis in a Human Immunodeficiency Virus-infected patient. Clin Infect Dis. 2002 Aug 1; 35(3):326-9.
    View in: PubMed
  102. Santra S, Barouch DH, Kuroda MJ, Schmitz JE, Krivulka GR, Beaudry K, Lord CI, Lifton MA, Wyatt LS, Moss B, Hirsch VM, Letvin NL. Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection. J Virol. 2002 Jun; 76(12):6376-81.
    View in: PubMed
  103. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, Letvin NL. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 2002 Jan 17; 415(6869):335-9.
    View in: PubMed
  104. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, Davies ME, Shiver JW, Letvin NL. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol. 2002 Jan 15; 168(2):562-8.
    View in: PubMed
  105. McKay PF, Schmitz JE, Barouch DH, Kuroda MJ, Lifton MA, Nickerson CE, Gorgone DA, Letvin NL. Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys. J Immunol. 2002 Jan 1; 168(1):332-7.
    View in: PubMed
  106. Barouch DH, Fu TM, Montefiori DC, Lewis MG, Shiver JW, Letvin NL. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol Lett. 2001 Nov 1; 79(1-2):57-61.
    View in: PubMed
  107. Letvin NL, Barouch DH, Montefiori DC. Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol. 2002; 20:73-99.
    View in: PubMed
  108. Barouch DH, Letvin NL. CD8+ cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. Curr Opin Immunol. 2001 Aug; 13(4):479-82.
    View in: PubMed
  109. Craiu A, Barouch DH, Zheng XX, Kuroda MJ, Schmitz JE, Lifton MA, Steenbeke TD, Nickerson CE, Beaudry K, Frost JD, Reimann KA, Strom TB, Letvin NL. An IL-2/Ig fusion protein influences CD4+ T lymphocytes in naive and simian immunodeficiency virus-infected Rhesus monkeys. AIDS Res Hum Retroviruses. 2001 Jul 1; 17(10):873-86.
    View in: PubMed
  110. Barouch DH, Santra S, Kuroda MJ, Schmitz JE, Plishka R, Buckler-White A, Gaitan AE, Zin R, Nam JH, Wyatt LS, Lifton MA, Nickerson CE, Moss B, Montefiori DC, Hirsch VM, Letvin NL. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol. 2001 Jun; 75(11):5151-8.
    View in: PubMed
  111. Barouch DH, Craiu A, Santra S, Egan MA, Schmitz JE, Kuroda MJ, Fu TM, Nam JH, Wyatt LS, Lifton MA, Krivulka GR, Nickerson CE, Lord CI, Moss B, Lewis MG, Hirsch VM, Shiver JW, Letvin NL. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J Virol. 2001 Mar; 75(5):2462-7.
    View in: PubMed
  112. Santra S, Barouch DH, Jackson SS, Kuroda MJ, Schmitz JE, Lifton MA, Sharpe AH, Letvin NL. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses. J Immunol. 2000 Dec 15; 165(12):6791-5.
    View in: PubMed
  113. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000 Oct 20; 290(5491):486-92.
    View in: PubMed
  114. Santra S, Barouch DH, Sharpe AH, Letvin NL. B7 co-stimulatory requirements differ for induction of immune responses by DNA, protein and recombinant pox virus vaccination. Eur J Immunol. 2000 Sep; 30(9):2650-9.
    View in: PubMed
  115. Barouch DH, Craiu A, Kuroda MJ, Schmitz JE, Zheng XX, Santra S, Frost JD, Krivulka GR, Lifton MA, Crabbs CL, Heidecker G, Perry HC, Davies ME, Xie H, Nickerson CE, Steenbeke TD, Lord CI, Montefiori DC, Strom TB, Shiver JW, Lewis MG, Letvin NL. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):4192-7.
    View in: PubMed
  116. Barouch DH, Letvin NL. DNA vaccination for HIV-1 and SIV. Intervirology. 2000; 43(4-6):282-7.
    View in: PubMed
  117. Barouch DH, Letvin NL. Cytokine-induced augmentation of DNA vaccine-elicited SIV-specific immunity in rhesus monkeys. Dev Biol (Basel). 2000; 104:85-92.
    View in: PubMed
  118. Barouch DH, Santra S, Steenbeke TD, Zheng XX, Perry HC, Davies ME, Freed DC, Craiu A, Strom TB, Shiver JW, Letvin NL. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol. 1998 Aug 15; 161(4):1875-82.
    View in: PubMed
  119. Kuroda MJ, Schmitz JE, Barouch DH, Craiu A, Allen TM, Sette A, Watkins DI, Forman MA, Letvin NL. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med. 1998 May 4; 187(9):1373-81.
    View in: PubMed
  120. Vessey SJ, Barouch DH, McAdam SN, Tussey LG, Davenport MA, O'Callaghan CA, Bell JI, McMichael AJ, Jakobsen BK. Engagement of a T cell receptor by major histocompatibility complex irrespective of peptide. Eur J Immunol. 1997 Apr; 27(4):879-85.
    View in: PubMed
  121. Davenport MP, Smith KJ, Barouch D, Reid SW, Bodnar WM, Willis AC, Hunt DF, Hill AV. HLA class I binding motifs derived from random peptide libraries differ at the COOH terminus from those of eluted peptides. J Exp Med. 1997 Jan 20; 185(2):367-71.
    View in: PubMed
  122. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996 Oct 4; 274(5284):94-6.
    View in: PubMed
  123. Barouch D, Friede T, Stevanovic S, Tussey L, Smith K, Rowland-Jones S, Braud V, McMichael A, Rammensee HG. HLA-A2 subtypes are functionally distinct in peptide binding and presentation. J Exp Med. 1995 Dec 1; 182(6):1847-56.
    View in: PubMed
  124. Barouch D, Davenport M, McMichael A, Reay P. A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. Int Immunol. 1995 Oct; 7(10):1599-605.
    View in: PubMed
  125. Krausa P, Barouch D, Bodmer JG, Browning MJ. Rapid characterization of HLA class I alleles by gene mapping using ARMS PCR. Eur J Immunogenet. 1995 Jun; 22(3):283-7.
    View in: PubMed
  126. Krausa P, Brywka M, Savage D, Hui KM, Bunce M, Ngai JL, Teo DL, Ong YW, Barouch D, Allsop CE, et al. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens. 1995 Apr; 45(4):223-31.
    View in: PubMed
  127. Barouch D, Krausa P, Bodmer J, Browning MJ, McMichael AJ. Identification of a novel HLA-A2 subtype, HLA-A*0216. Immunogenetics. 1995; 41(6):388.
    View in: PubMed
  128. Krausa P, Barouch D, Bodmer JG, Hill AV, Mason C, McMichael AJ, Browning MJ. Characterization of a novel HLA-A2 variant, A*0214, by ARMS-PCR and DNA sequencing. Immunogenetics. 1995; 41(1):50.
    View in: PubMed
  129. Barouch DH, Harrison SC. Interactions among the major and minor coat proteins of polyomavirus. J Virol. 1994 Jun; 68(6):3982-9.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Barouch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (391) concept(s)
_
Co-Authors
See all (53) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_